Interesting ImagesIncidental 18F-Fluciclovine Uptake in a Warthin Tumor of the Parotid Gland in a Patient Undergoing PET/CT Imaging for Biochemical Recurrent Prostate CancerBitar, Ryan BM*; Martiniova, Lucia PhD†; Bell, Diana MD†; Ravizzini, Gregory MD†Author Information From the *The University of Texas Health Science Center at San Antonio †The University of Texas MD Anderson Cancer Center, Houston, TX. Received for publication August 31, 2019; revision accepted November 24, 2019. Gregory Ravizzini is the recipient of grant funding from Blue Earth Diagnostics, Inc, related to a clinical trial involving 18F-fluciclovine in patients with prostate cancer. Other authors report no conflict of interest relevant to this work. Correspondence to: Gregory C. Ravizzini, MD, Department of Nuclear Medicine, UT MD Anderson Cancer Center, 1400 Pressler St, Unit 1483, Houston, TX 77030. E-mail: email@example.com. Online date: January 30, 2020 Clinical Nuclear Medicine: April 2020 - Volume 45 - Issue 4 - p e208-e210 doi: 10.1097/RLU.0000000000002938 Buy Metrics Abstract A 67-year-old asymptomatic man with biochemical recurrent prostate cancer underwent 18F-fluciclovine PET/CT for restaging to determine subsequent treatment strategy. PET/CT images were obtained from the proximal thighs to the vertex of the skull, after the intravenous administration of 362.6 MBq (9.8 mCi) of 18F-fluciclovine. PET/CT imaging demonstrated a focus of abnormally increased 18F-fluciclovine uptake corresponding to a small nodularity in the left parotid gland. Subsequent ultrasound-guided fine-needle aspiration biopsy of the lesion revealed histopathology compatible with a benign Warthin tumor. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.